Research programme: AAV-based gene therapies - Neuralgene

Drug Profile

Research programme: AAV-based gene therapies - Neuralgene

Alternative Names: PRCN 226; PRCN 408; PRCN 829

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuralgene
  • Developer Neuralgene; Precision StemCell
  • Class Gene therapies
  • Mechanism of Action Complement factor H modulators; Complement system protein inhibitors; Gene modulators; Growth factor receptor modulators; Neurogenesis stimulants; TDP-43 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Macular degeneration; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Colombia
  • 16 Jul 2016 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Colombia
  • 16 Jul 2016 No recent reports of development identified for research development in Macular-degeneration in Colombia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top